Real-world efficacy and safety of Ledipasvir plus Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir +/- Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience

Date
2020
Author
Sumer, Hale
Inci, Ismail
Simsek, Halis
Ozdogan, Osman
Coban, Mehmet
Poturoglu, Sule
Ayyildiz, Talat
Yapali, Suna
Gunsar, Fulya
Akdogan, Meral
Ozenirler, Seren
Akyildiz, Murat
Sezgin, Orhan
Ozdogan, Osman
Kaymakoglu, Sabahattin
Besisik, Fatih
Karasu, Zeki
Idilman, Ramazan
Guzelbulut, Fatih
Balkan, Ayhan
Vatansever, Sezgin
Danis, Nilay
GÜNEŞ, Şevkican
Demircan, Melek
Soylu, Aliye
Yaras, Serkan
Kartal, Aysun
Kefeli, Ayse
Gunduz, Feyza
Yalcin, Kendal
Erarslan, Elife
Aladag, Murat
Harputluoglu, Murat
Ozakyol, Aysegul
Kacar, Sabite
Dincer, Dinc
Doganay, Levent
Gokturk, Huseyin Savas
Mert, Ali
Cosar, Arif Mansur
Dursun, Hakan
Atalay, Roni
Akbulut, Sabiye
Balkan, Yasemin
Koklu, Hayrettin
Degertekin, Bulent
Demir, Mehmet
AKARCA, ULUS SALİH
Kani, Haluk Tarik
Ucbilek, Enver
Yildirim, Emre
Temel, Tuncer
Akarsu, Mesut
Akin, Mete
Albayrak, Bulent
Sen, Ilker
Alkim, Huseyin
Uyanikoglu, Ahmet
Irak, Kader
Oztaskin, Sinem
Ugurlu, Cagri Burak
Gurel, Selim
Nuriyev, Kenan
Metadata
Show full item record
Abstract
Background/Aims: This study aimed to evaluate the real-life efficacy and tolerability of direct-acting antiviral treatments for patients with chronic hepatitis C (CHC) with/without cirrhosis in the Turkish population.
URI
http://hdl.handle.net/20.500.12627/178906
https://doi.org/10.5152/tjg.2020.20696
Collections